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AbstractMalaria has been shown to strongly predispose patients in areas of malaria endemicity to bacteremia with severe outcomes, thus justifying the use of antibiotics in combination with antimalarial therapy in patients with severe malaria. This study describes a High-Performance Liquid Chromatographic (HPLC) method for simultaneous determinations of 
Ciprofloxacin (CPN), Quinine (QN), and its major metabolite, 3-Hydroxyquinine (3-HQN), in human plasma. Following a 
simple precipitation with acetonitrile, chromatographic separation was achieved on a reversed-phase Agilent Zorbax (CN) column (5 µm, 150 X 4.6 mm i.d) using a mobile phase consisting of acetonitrile: potassium dihydrogen phosphate (pH 
= 2.8; 0.02 M) (42:58, v/v). Retention times for CPN, 3-HQN, IS and QN were 2.7, 3.3, 3.6 and 4.9 minutes respectively. 
The limits of detection and validated lower limits of quantitation were 30 and 70 ng/ml for both QN and 3-HQN while 
the corresponding values were 50 and 100 ng/ml for CPN, respectively. The new HPLC method here developed, when compared with previous methods for the analysis of either or both drugs is simple, rapid, selective, reproducible and cost-
effective. It is also suitable for conducting a simultaneous therapeutic monitoring of quinine and ciprofloxacin  in patients 
when concomittantly administered as demonstrated in five healthy volunteers.
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1. Introduction
Co-morbidity of malarial and bacterial infections is a 
common phenomenon in the world today particularly in 
the tropics. WHO malaria report for year 2014 revealed 
that up to 198 million cases of malaria were reported in 
2013 and out of this, the death toll was up to 584,0001. 
Similarly, bacterial infections are ravaging in this same 
region since a large number of hospital visits results 
from bacterial infections. A study in Kenya provided 
evidence that Plasmodium falciparum infection increases 
the risk for bacteraemia, particularly for gram-negative 
invasive infections2,3. Co-morbidity of malaria and 
bacterial infections could warrant co-administration of 
antimalarial and antibacterial drugs. 
Artesunate and Quinine (QN) injections are the drugs 
of choice for severe or cerebral malaria and oral dosage 
form of these drugs are to be considered for follow-up 
treatment when the patient is fully conscious. QN is a 
more popular option in paediatrics and in resource-
limited regions such as sub-Saharan Africa essentially 
because of availability challenges couple with uneven 
distribution of the available artesunate finished products 
and high cost associated with artesunate therapy in the 
region4. Children and some adults with severe malaria are 
likely to receive QN either as injection, oral or rectal. 
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Ciprofloxacin (CPN) is a fluoroquinolone often pre-
scribes especially for lower respiratory tract infections 
probably because of its good tissue penetration and 
safety profile, and a broad spectrum of action that cov-
ers a number of clinically important pathogens, especially 
Gram-negative bacteria including Pseudomonas aerugi-
nosa, against which very few effective oral antibiotics are 
available5. The use of CPN in paediatrics has been limited 
due to the fear that it caused arthropathy in weight-bear-
ing joint of juvenile animals. However, a recent review 
depicted that different investigators have used CPN in 
paediatric patients and the general experience is that it is 
safe and effective in children also6. 
Cinchonism and cardiac arrhythmias are common 
toxicity of QN therapy and this toxicity may be connected 
with the plasma concentration of the drug. In the same 
vein, cardiac arrhythmias and arthropathy are postulated 
to be associated with quinolones administration. Thus, 
there may be increased manifestations of these toxicities 
in a circumstance where CPN and QN are to be adminis-
tered concurrently. This is adduced to the fact that toxicity 
is related to the drugs exposure in the plasma. In order to 
achieve a good clinical outcome particularly in paediat-
rics, therapeutic drug monitoring of the plasma levels of 
QN and CPN when they are co-administered will be of 
great benefit. This will help to adjust the dosage regimens 
of the drugs appropriately in order to meet the therapeu-
tic targets or needs without or with minimal unpleasant 
effects.
 In severe P. falciparum malaria, a peak plasma quinine 
level of 10–15 µg/ml was recommended for effective para-
site clearance and tolerable side effects, although, these 
levels were reported as toxic in non-malaria subjects7. 
Also, monitoring the plasma levels of 3-HQN along with 
QN is necessary since this major metabolite is reported to 
have a higher toxicity than QN, but much less potent as 
an antimalarial8. To conduct a successful therapeutic drug 
monitoring, a suitable simple, rapid and cost-effective 
analytical procedure to quantify the analytes, is of para-
mount important.
 A number of bioassay techniques have been described 
in literatures to quantify CPN and QN separately from 
biological fluids. For instance HPLC determination of 
quinine with UV detector developed by Babalola et al and 
Soyinka et al9,10, HPLC with fluorescence to detect quinine 
by Wanwimolruk et al and Mirghani et al11,12. Similarly, a 
number of HPLC methods have been described for deter-
mination of ciprofloxacin in biological samples but some 
of them are limited in application owing to the long run 
time, requirement for large plasma volume and cum-
bersome extraction procedure13–16. In addition to all of 
these shortcomings, to our knowledge, an assay method 
to determine both QN and CPN simultaneously in the 
plasma has not been described. Thus, the objective of this 
study is to develop and validate a modest, easily operable 
and reliable HPLC method for the concurrent quantifica-
tions of QN, CPN and 3-HQN in human plasma.
2. Experimental
2.1 Chemical and Reagents
Ciprofloxacin (Cyplox® from Medreich, Pharmaceutical 
Company) and quinine tablets (Quinmax®) were 
purchased locally from a  retail pharmacy outlet. 
Ciprofloxacin hydrochloride (Figure 1) was sourced from 
AK Scientific Inc. Union City (USA) while quinine sul-
phate (Figure  1) was purchased from BDH chemicals 
(Poole, UK). 3-Hydroxyquinine (Figure 1) was donated 
by Prof. James M. Cook, University of Wisconsin, USA. 
Acetonitrile (HPLC grades), potassium dihydrogen 
phosphate (analar grade) and hydrochloric acid were all 
purchased from Sigma–Aldrich Chemicals (Steinheim, 
Germany). Perchloric acid (Hopkins and Williams, Essex, 
UK) was of analar grade. Pyrimethamine was obtained 
from Swiss Pharma Nig Ltd.
2.2 Instrumentation
The chromatographic system consisted of an Agilent 
1100 series liquid chromatography (Agilent technologies, 
Palm alto, USA) using a reversed-phase Agilent Zorbax 
Cyano (CN) column (5 µm, 150 X 4.6 mm i.d) fitted with 
a quaternary pump and a Diode array UV detector (DAD, 
190-900 nm). DAD was connected to a computer and the 
signals were recorded therein as chromatograms. Sample 
injection was through a Rheodyne model 7725 valve 
(California; USA) fitted with a 20 µl loop. Vortex mixer 
(Gallenkamp, London, UK) and centrifuge (Gallenkamp) 
were used in the extraction procedure.
2.3 Chromatographic Conditions
Chromatographic separation was achieved at ambient 
temperature on a reversed-phase Agilent Zorbax (CN) 
column (5 µm, 150 X 4.6 mm i.d). Isocratic elution was 
performed using a mobile phase consisting of acetonitrile 
and potassium dihydrogen phosphate buffer (pH =2.8 ; 
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solutions of ciprofloxacin, quinine and its metabolite. 250 
µL of drug-free plasma samples were spiked with 50 µL 
of internal standard solution (10 µg/mL pyrimethamine) 
and standard solutions (between the range of 0.05 –10 
µg/mL) of ciprofloxacin, quinine and its metabolite. To 
each sample, acetonitrile was added to make up to one-
mL and the samples were sequentially vortex-mixed 
and centrifuged for 1 and 5 minutes respectively and the 
supernatant (20 µl) was injected into HPLC column. The 
Peak Area Ratios (PAR) were generated from the ratio of 
response (peak area) of the analytes to that of the inter-
nal standard. A plot of PARs versus concentrations of the 
standard solutions was done. 
2.7  Recovery, Accuracy and Precision 
Studies
Blank plasma samples were spiked with standard 
solutions of ciprofloxacin, quinine and 3-hydroxyquinine 
to yield concentrations of 0.5, 5.0 and 10.0 µg/ml for 
ciprofloxacin and quinine and 0.2, 2.0 and 10.0 µg/ml for 
3-hydroxyquinine. Then, the samples were taken through 
extraction procedure. The absolute recovery, expressed 
as percentage, was determined by comparing the PAR 
obtained from the extracted samples with the neat injection 
of reference samples of the same concentration. The PAR 
was converted to concentration using calibration curves for 
each of the analytes. Accuracy of the analytical method for 
0.02 M) pH was adjusted with a few drops of 60% v/v per-
chloric acid (42:58 v/v) and the effluent was monitored 
by UV detection at 254 nm for quinine and 3-hydroxy-
quinine and 275 nm for ciprofloxacin. The buffer solution 
was filtered through 0.45μm membrane filter. The mobile 
phase was pumped through the column at a flow rate of 
1.0 mL/min and the injection volume was 20 μL.
2.4 Preparation of Stock Solution
1.0 mg/ml of quinine base, 3-hydroxyquinine and cipro-
floxacin were prepared in 0.1 M hydrochloric acid and 
various concentrations of working solutions were pre-
pared from the stock solutions
2.5  Sample Preparation and Extraction 
Procedure
To 250 µl of plasma sample placed in a 2-ml eppendorf 
tube was added 50 µl of 10µg/mL pyrimethamine solu-
tion (internal standard). 700 µl of acetonitrile was added 
and the content was vortex-mixed for 1 min and centri-
fuged for 5 min at 3000 g. 20 µl of a clean supernatant was 
injected into HPLC column.
2.6 Calibration Curve
Calibration curves were constructed based on the rela-
tionship between the peak area ratios and the standard 
Figure 1. Chemical Structures of Ciprofloxacin, Pyrimethamine, Quinine, Quinine salt and its metabolite.
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each of the three analytes was determined by the percentage 
ratio of the estimated concentrations to that of the actual 
concentrations of the reference standard prepared. Also 
the coefficients of variation of the estimated concentrations 
were determined and used for the assessment of precision.
2.8 Application of Analytical Method
Ethical clearance was sought and obtained from 
the Health Research Ethics Committee (HREC No: 
IPHOAU/12/124)), Institute of Public Health, Obafemi 
Awolowo University, Ile Ife. Five healthy volunteers with 
body weight ranging from 45 to 85 Kg (63.2 ± 14.5 Kg) 
and age ranging from 25 to 40 years, received 500 mg 
ciprofloxacin twice daily for one week and 600 mg qui-
nine was administered to each of the volunteers as oral 
dose concurrently with 11th dose of ciprofloxacin. Then, 
venous blood samples were collected into EDTA bottles 
just before the concurrent drug administration and at 1, 
2, 4, 6, 8, 12 and 24 hours after drug administration. The 
blood samples were centrifuged at 3000 x g for 5 min to 
obtain the plasma which was analysed for ciprofloxacin, 
quinine and 3-hydroxyquinine concentrations following 
the procedures described above. The maximum plasma 
drug concentration Cmax and Tmax were obtained by visual 
inspection of the concentration–time data. The area 
under plasma concentration-time curve (AUC0-t) was 
computed using the log linear trapezoidal method where 
t0 = 0 corresponded to C0 = 0 for QN and 3-HQN but this 
was considered as the trough for ciprofloxacin. AUC0-∞ 
was obtained from the sum of AUC0-t and Ct/Lz. Lz is the 
elimination rate constant obtained by linear regression 
analysis of the terminal phase of the curve. 
3. Results
Sample chromatogram is shown in Figure 2 which rep-
resents an output from the HPLC method described 
above. It clearly indicated that the peaks ascribed to QN, 
3-HQN and CPN were well separated from one another 
and they were not in any way interfered with the endog-
enous compounds. The retention times were 2.7, 3.3 and 
4.9 minutes for CPN, 3-HQN and QN respectively and 
the run time was 7 minutes. The method was specific for 
these analytes because there was no interference with the 
peaks of compounds such as paracetamol, trimethoprim, 
sulphamethoxazole, proguanil and chlorpheniramine. 
The lowest detectable concentration or Limit of Detection 
(LOD) was taken as a concentration producing a peak 
Figure 2. High-performance liquid chromatogram of extracted plasma sample obtained from a volunteer at 2 h following 
concurrent administration of a single 600mg oral dose of quinine sulphate with multiple oral doses of ciprofloxacin (500mg 12 
hourly for one week). The quinine dose was co-administered with the 11th ciprofloxacin dose. The sample was spiked with 50 
µl of 10 µg/ml pyrimethamine. CPN = Ciprofloxacin, 3-HQN = 3-Hydroxyquinine, IS = Internal Standard (pyrimethamine) 
and QN = Quinine. 
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of three times the baseline noise and this parameter was 
found to be 10 ng/ml for QN, 3-HQN and 40 ng/ml for 
CPN. The lowest concentrations of the analytes which 
are assayable with this method with an acceptable level 
of precision and accuracy1 were 30 ng/ml for QN and 
3-HQN while that of CPN was 70 ng/ml. Linear curves 
were obtained for QN and 3-HQN in the plasma with 
correlation coefficients of 0.999 with the range of linear-
ity between 50 ng/ml to 10,000 ng/ml while the linearity 
for CPN is between 100 ng to 10,000 ng/ml. The results 
for the accuracy, recovery and precision for the drugs 
are indicated in Table 1. All the values for precision and 
accuracy were within the normal limits. The mean recov-
ery for the three analytes were between 90.8 to 99.2 % at 
a lower, a middle and higher concentration within the 
range of linearity.
The average plasma concentration-time profiles of 
QN, 3-HQN and CPN following concomitant adminis-
tration of multiple doses of CPN (500mg 12 hourly for 1 
week) and a single 600mg oral dose of quinine sulphate 
to each of seven volunteers are illustrated in Figure 3. The 
plasma exposure of ciprofloxacin was determined within 
a dosing interval of 12 hour after the 11th oral dose as this 
is acceptable measures for evaluation of pharmacokinet-
ics of a drug when steady-state drug levels are reached 
in a multiple dose regimen. The derived pharmacoki-
netic parameters for QN, 3-HQN and CPN are shown in 
Table 2.
Table 1. Precision, recovery and accuracy of the analytical method










 QN 6 0.5 3.3 6.0 94.7±5.7 96.7±4.6
6 5.0 4.9 4.4 96.3±4.3 94.6±4.6
6 10.0 1.5 2.3 101.2±2.3 95.9±3.3
3-HQN 6 0.5 7.7 3.2 94±3.0 92±7.4
6 5.0 3.9 2.6 98.0±2.6 93.6±4.2
6 10.0 3.6 2.9 98.7±2.9 95.3±3.9
CPN 6 0.5 5.6 11.6 98.2±7.2 99.2±4.5
6 5.0 6.1 10.2 102.9±10.5 90.8±11
6 10.0 6.1 3.1 99.3±4.5 99.2±3.6
Figure 3. Mean Plasma Concentration vs. time Profiles of Quinine (QN), 3-Hydroxyquinine (3-HQN) and Ciprofloxacin 
(CPN) after concurrent administrations of a single 600mg oral dose and multiple oral doses of 500 mg 12 hourly to each of 
sevenhealthy volunteers. 
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4. Discussion
A simple protein precipitation applied in order to extract 
the analytes was efficient. A clear and clean supernatant 
from plasma was produced after a single step extraction 
with acetonitrile and there was no interference with the 
endogenous compounds. QN, 3-HQN and CPN were 
completely resolved to the baseline with a short run-
time of 8 min. In this work, the retention times for CPN, 
3-HQN and QN were 2.7, 3.3 and 4.9 minutes respec-
tively. This offers an excellent efficiency in terms of the 
time it will require to work on both the extraction and 
chromatographic procedures. The method also requires 
low plasma volume of 250 µl compared with higher 
plasma volume used in other methods which makes it 
to be suitable for most patients particularly paediat-
rics. Similarly, most other methods described for QN 
and CPN involved cumbersome liquid-liquid extrac-
tion, whereas, a-step protein precipitation approach 
was adopted in this method which removed a more 
laborious extraction procedure. On this basis, the newly 
developed method has an edge of simplicity, rapidity and 
economical when compared to some of the previously 
developed HPLC methods to determine ciprofloxacin, 
quinine and its principal metabolite9–17. The percentage 
recovery and evidence of accuracy of over 90% for each 
of the analytes also lend credence to the effectiveness of 
this method. The composition of the mobile phase 52% 
acetonitrile and 48% 10 nm of potassium dihydrogen 
phosphate buffer also make the method very affordable 
to run. 
Therapeutic drug monitoring (TDM) is suggested 
for ciprofloxacin where the ratio between the mini-
mum inhibitory concentration (MIC) and the plasma 
concentration or area under concentration-time pro-
file is considered as a predictor of its effectiveness19,20. 
MIC is an index to measure or predict clinical efficacy 
of antibacterial and this factor depends on both the 
effective plasma concentration and the ability of the 
antibacterial to penetrate the site of infection19. Difficult-
to-predict pharmacokinetics of ciprofloxacin can occur 
in critically-ill patients and because of this variability in 
pharmacokinetics; TDM may be of a great importance 
to avoid treatment failure and emergence of resistance19. 
For this purpose, sampling times that correspond with 
the trough and peak concentrations are usually con-
sidered and both were measurable with this method. 
Accumulation of ciprofloxacin in the plasma or serum 
necessitate dose reduction whereas rapid clearance from 
the biological fluids may call for upward review of dos-
age regimen. The ratio of AUC to MIC of 125 is usually 
considered for treatment of gram-negative organism. 
Similarly, Cmax- to-MIC ratio of 8-10 is considered 
as a surrogate value for effectiveness of ciprofloxacin. 
Clinicians may want to rely on this parameter in order 
to prevent exposure to excess plasma concentration 
especially in paediatrics where the risk of developing 
musculoskeletal toxicity is probable. 
This method was applied to pharmacokinetic studies 
on ciprofloxacin and quinine after administrations of a 
single dose of 600 mg quinine and 11th 500 mg oral dose 
of ciprofloxacin to five healthy volunteers. The average 
area under the curve (AUC0-∞), Cmax, Tmax and half-life 
(t1/2) for ciprofloxacin are 22.1 µg/ml*hr, 3.6 µg/ml, 2 h 
and 5.7 h respectively. Ciprofloxacin pharmacokinetics 
is dose-dependent where the values for pharmacoki-
netic parameters vary with doses. The values obtained 
from this study were comparable with the established 
figures15,17,19,21. Derived pharmacokinetic parameters har-
vested for quinine after a single oraladministration  in 
the presence of ciprofloxacin were 41.62 µg/ml*hr, 1.64 
µg/ml, 3.5 h and 21.4 h  for AUC, Cmax, Tmax and half-
life (t1/2) respectively and a clearance of 16 L/h. There 
was a reduced clearance and prolonged t1/2 when the data 
were compared with the established figures22,23. Also the 
plasma exposure of 3-HQN was low when compare to 
literature values obtained from healthy volunteers. A 
recent report revealed that CPN is capable of inhibit-
ing the metabolism of QN in healthy volunteers which 
resulted in about 39% increase in plasma concentration 
of QN24. CPN depresses the formation of 3-hydroxy-
quinine (3-HQN) through the inhibition of cytochrome 
Table 2. Some derived pharmacokinetic parameters 
for quinine, ciprofloxacin and 3-hydroxyquinine
PK parameters QN CPN 3-HQN
Cmax (µg/ml) 1.64 ± 0.11 3.6± 1.9 0.39 ± 0.06
Tmax (h) 3.5 ± 0.36 2.14± 1.34 4.92 ± 1.05
AUC(0-t) (μg/ml.h) 32.38 ± 2.85 22.14± 14.65 9.54 ± 1.22
AUC(0-∞) (μg/ml.h) 41.62 ± 4.04 29.17± 18.4 14.83 ± 2.04
t(½)(h) 21.43 ± 0.93 5.68± 0.47 31.58 ± 3.18
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P450 3A4 (CYP3A4). This is suggestive of metabolic 
interaction between quinine and ciprofloxacin. This type 
of interaction would result in increased QN plasma levels 
with associated toxicities
5. Conclusion
In conclusion, the HPLC method described is very sim-
ple, reproducible, and rapid. The method is also accurate, 
selective and cost-effective. It will help in conducting 
either individual or simultaneous determination of qui-
nine and ciprofloxacin for TDM pursuit based on their 
Cmax and AUC. It will also facilitate the monitoring of qui-
nine metabolite.
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